GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
What GlaxoSmithKline files
- Others98
- Investor Meet25
- Updates20
- Important16
- Board Meeting12
- Dividend/Bonus9
Company corrected a typo in a postal ballot notice for Mr. Akshikar's basic salary, changing it from Rs. 2.40 Cr to Rs. 0.24 Cr per month. This clarifies executive compensation.
GSK received a tax refund of ₹4.99 Cr for tax year 2025-2026, boosting its tax paid assets. This is a positive cash inflow for the company.
GSK Pharma reported strong Q1 consolidated revenue of ₹938.44 Cr and profit of ₹237.18 Cr. Key management changes include Mr. Subesh Williams' resignation, Ms. Karine J F Natland's appointment as Non-Executive Director, and Mr. Bhushan Akshikar's re-appointment as MD for two years.
GSK India reported strong Q1 results: Revenue up 15% to INR 924 Cr, PAT up 24% to INR 253 Cr. Growth fueled by core portfolio, innovative oncology, and vaccines. Upcoming launches include Blenrep and Arexvy.